Andrew Tsai

Stock Analyst at Jefferies

(0.3)
# 2786
Out of 5,441 analysts
28
Total ratings
Success rate
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
SRPT Sarepta Therapeutics
Maintains: Buy
40 35
17.95 94.99% 3 Jul 24, 2025
STOK Stoke Therapeutics
Initiates Coverage On: Buy
30
13.14 128.31% 1 Jul 18, 2025
BBIO BridgeBio Pharma
Initiates Coverage On: Buy
70
48.24 45.11% 1 Jul 14, 2025
VRNA Verona Pharma
Maintains: Strong Buy
95 110
105.25 4.51% 1 Jun 11, 2025
RCKT Rocket Pharmaceutica...
Downgrades: Hold
29 3
2.93 -14.68% 2 May 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
200
103.95 92.4% 1 Apr 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
19 27
17.73 52.28% 2 Mar 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
5 1
0.55 -9.09% 1 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
4 13
0.56 2221.43% 2 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
35
14.37 143.56% 1 Jul 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10 21
21.55 -2.55% 1 Mar 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
33
3.06 978.43% 1 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
1 15
2.81 433.81% 2 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Hold
3
1.03 191.26% 1 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
32 3
n/a n/a 2 Jun 23, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
8.05 148.45% 1 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
55 70
131.87 -46.92% 2 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
27
3.96 581.82% 1 Sep 1, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
44.96 -59.96% 1 Nov 23, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
16 23
34.12 -32.59% 1 Jun 1, 2020